In addition, a clinical trial (phase 2 study) with zilucoplan (complement C5 inhibitor) is ongoing to assess the efficacy and safety of zilucoplan in improving oxygenation and short- and long-term outcomes in COVID-19 patients with acute hypoxic respiratory failure [43]. Here, C5 is linked to COVID-19.